Search the latest HealthRX.com articles on GLP-1 medicine, hormone therapy, peptides, labs, costs, coverage, side effects, and dosing. Latest clinical articles Showing 300 of 23,300 clinical reviews. What Drives 5-Amino-1MQ Pricing 5-amino-1MQ pricing varies by purity testing, batch source, and seller type, not by proven efficacy, since no dosing or quality standard is FDA-established. 5-Amino-1MQ 'Dosing': What Vendors Claim and Evidence Supports No validated human dose of 5-amino-1MQ exists. Rodent studies inform mechanism, not milligrams. Here is what the evidence actually supports. Editorial: 5-Amino-1MQ Is a Promising Mouse Drug Being Sold to Humans 5-amino-1MQ has strong rodent NNMT-inhibition data and no human trials. This editorial argues the mouse-to-human translation gap is being sold as settled science. 5-Amino-1MQ's US Regulatory Status 5-amino-1MQ has no FDA-approved use and is not on the 503A bulks list. Here is what its current regulatory status actually means for buyers. 5-Amino-1MQ and Muscle: The Regeneration Research 5-amino-1MQ is studied in preclinical models for NNMT-linked muscle metabolism; no cited human sarcopenia trial has tested the compound itself as of Sept 2026. 5-Amino-1MQ, NAD+, and Methylation: The Biochemistry 5-Amino-1MQ inhibits NNMT, an enzyme linking methylation and NAD+ salvage; the mechanism is well studied preclinically, human metabolic effects are not. Why 5-Amino-1MQ Is Sold as a Capsule: Bioavailability Notes 5-amino-1MQ is capsule-dosed because it is a small molecule, not a peptide, but oral rat pharmacokinetic data does not establish human bioavailability or efficacy. 5-Amino-1MQ Safety: What Is Known and What Is Not No human safety data exist for 5-amino-1MQ. Here is what animal and enzymology research suggests about risk, and what remains unverified. 5-Amino-1MQ vs Berberine for Metabolic Health 5-amino-1MQ has no human trials; berberine has human RCT history. Compare evidence tiers, mechanisms, and what each gap means for decisions. 5-Amino-1MQ vs GLP-1 Medications: No Contest, Explained 5-amino-1MQ has no human weight-loss trials; semaglutide and tirzepatide have large randomized trials and FDA approval. Here is why that gap matters. 5-Amino-1MQ for Weight Loss: Mouse Data vs Marketing 5-amino-1MQ weight loss evidence comes entirely from mouse studies. No human trials exist. Here is what the rodent data actually showed. The 5-Amino-1MQ Market: What to Watch For 5-amino-1MQ is sold as an unregulated research chemical with no FDA-approved use. Here is how to read purity claims and vendor red flags. How NNMT Inhibition Works: The Metabolic Logic 5-amino-1MQ blocks the NNMT enzyme in rodent studies, altering NAD+ and methylation balance in fat cells; human mechanism data remain unpublished as of 2026. What Is 5-Amino-1MQ? The NNMT Inhibitor, Explained 5-amino-1MQ is an experimental small-molecule NNMT inhibitor, not a peptide or approved drug. Evidence is mostly preclinical. DSIP Clinical Trials: The Complete History DSIP's 1981-1998 European trials showed inconsistent insomnia results in small studies; development stalled, and FDA rejected its 2026 compounding bid. What Drives DSIP Pricing DSIP prices vary because it is an unapproved, non-503A compounded peptide sold in an unregulated gray market, not because of graded quality tiers. DSIP Dosing: What Protocols Exist and What Supports Them No validated human DSIP dosing protocol exists. One small trial and scattered anecdotal regimens are often confused with clinical guidance. Here is the difference. Editorial: Why the FDA Committee Said No to DSIP DSIP's advisory committee rejection traces to thin, decades-old human trials. Here is the evidence gap and what data could actually close it. DSIP FDA Status: Withdrawn Nomination, Rejected Recommendation DSIP has no FDA-approved use. Its bulks nomination was withdrawn and an FDA advisory committee voted against adding it in 2026. DSIP for Sleep: What the Research Actually Shows DSIP's name promises delta sleep, but human trial evidence is one small 1992 study. Here is what it found, and what it did not. How DSIP Might Work: Mechanism Hypotheses DSIP has no confirmed receptor or validated mechanism. Here is what the hypotheses actually claim, what evidence supports them, and what remains unproven. DSIP and Pain: The Analgesia Research Thread DSIP's pain-relief reputation traces to old, small studies not represented in current verified literature. Here is what is actually established versus assumed. DSIP Reconstitution and Storage Guide DSIP has no FDA approval and no published stability data; general peptide handling principles apply, but sterility and dosing risks remain unresolved. DSIP Side Effects and Safety: The Documented Record DSIP's human safety data comes from three small older trials; most research is rodent-based, and unregulated sourcing is the larger practical risk in 2026. DSIP and the Stress Axis: Cortisol and ACTH Research DSIP's link to cortisol and ACTH rests on old, unreplicated studies; current HPA-axis research does not include DSIP-specific trials in this evidence set. DSIP vs Melatonin: An Honest Comparison DSIP has thin, largely animal or non-English human data and no FDA status; melatonin is a widely used OTC supplement with a far larger published record. DSIP vs Prescription Sleep Medications DSIP has no FDA approval and thin trial evidence; zolpidem and trazodone are approved options with different risk tradeoffs. Here is an honest comparison. How People Get DSIP, and the Risks at Each Route DSIP has no FDA-approved use and no legal 503A compounding pathway. Here is how it actually reaches buyers, and the red flags at each route. What Is DSIP? The Delta Sleep-Inducing Peptide, Explained DSIP (emideltide) is a 1970s rabbit-brain-derived peptide with no FDA-approved use and thin, mostly small or animal-based sleep evidence. Follistatin-344 'Dosing': Why No Real Protocol Exists

No validated human dosing for Follistatin-344 exists. Vendor protocols are unsourced extrapolations, not evidence. Here is what the data actually shows. Follistatin-344 vs 315: The Splice Variants Explained Follistatin-344 is named for a precursor length, not the FST315 form that actually circulates in human serum. The splice variant biology, explained plainly. What Drives Follistatin-344 Pricing Follistatin-344 prices vary widely because of protein synthesis cost, purity claims, and zero regulatory price anchoring, not proven potency differences. Editorial: Follistatin-344 Is Mostly a Story We Tell Ourselves Belgian Blue cattle photos are not human trial data. Follistatin-344 has no controlled human evidence for muscle gain, and the gap matters. Follistatin-344's US Regulatory Status Follistatin-344 has no FDA-approved use, is not on the 503A bulks list, and lacks human clinical trial evidence for any claimed benefit. Follistatin Gene Therapy Trials: What Actually Happened Follistatin trials used AAV gene therapy in Becker MD and IBM patients, not injectable peptide vials. Here is what the published data actually shows. Follistatin and Muscle Growth: Animal Data vs Human Reality Follistatin-344 grows muscle dramatically in mice and cell models. Human clinical trial data on follistatin-344 for muscle growth does not exist. Here is the actual evidence map. How Follistatin Blocks Myostatin (and Activin) Follistatin-344 blocks myostatin by structural binding, but the same domain also binds activin non-selectively, which is the real safety question. Follistatin, Exercise, and Natural Levels Exercise and weight loss change circulating follistatin and FSTL1 in trials, but no study measured the injectable peptide Follistatin-344 itself. Follistatin-344 Risks: Off-Target Effects Worth Taking Seriously Follistatin-344 blocks activin signaling, which also governs fertility, fibrosis, and bone remodeling. Human safety data for this compounded peptide are absent. Follistatin-344 vs Creatine: An Uncomfortable Comparison Creatine has hundreds of human trials and a safety record; Follistatin-344 has none in humans. Here is what that gap actually means for you. The Follistatin-344 Market: Quality and Authenticity Risks Follistatin-344 is a folded protein, not a simple peptide chain, which makes counterfeit and degraded vials far harder to detect than with small peptides. The Myostatin Inhibitor Landscape in 2026 Follistatin-344 sits outside every legitimate myostatin-inhibitor track: not FDA-approved, not on the 503A bulks list, and untested in humans. What Is Follistatin-344? The Myostatin-Binding Protein Follistatin-344 is a myostatin-binding splice variant studied mainly in gene-therapy models; no FDA approval or human injectable safety data exist. How People Get Selank, and What to Watch For Selank has no FDA-approved use and no 503A compounding pathway. Here is the access reality, the red flags to watch for, and what remains unverified. Selank for Anxiety: Reading the Actual Evidence Selank's anxiolytic evidence comes from Russian human trials and animal models, not FDA-reviewed trials. Here is what the studies actually show. What Drives Selank Pricing Selank cost varies by purity testing, peptide length, batch size, and vendor compliance rather than dosing form. No FDA-approved product exists to anchor pricing. Selank Dosing: Nasal Spray vs Injection Selank has no approved or validated dose. This compares reported intranasal and injected regimens from research use and flags what remains unverified. Editorial: Selank Is Interesting. The Evidence Base Has a Geography Problem Selank's anxiolytic evidence comes almost entirely from Russian-language trials. Here is what independent replication would need to show. Selank's US Regulatory Status, Plainly Selank has no FDA approval, is not FDA-cleared as a drug, and is not on the 503A bulk substances list as of September 2026. Here is what that actually means. Selank's Immune and Interferon Research Selank is structurally related to tuftsin, an immune peptide, but no cited study measures Selank's effect on interferon or immune signaling in humans. Selank's Mechanism: Tuftsin, GABA, and BDNF Threads Selank's proposed mechanisms (tuftsin-like immune signaling, GABAergic tone, BDNF expression) rest on rodent studies only; no confirmed human mechanism exists. Selank's Nootropic Claims vs the Evidence Selank is marketed as a nootropic for memory and focus, but no human cognition trials exist. This audit checks each claim against the actual literature. Selank Nasal Spray: Preparation and Handling Selank nasal spray has no published stability data. Here is what is known about peptide handling and how to reason through storage decisions. Selank Side Effects and Safety Profile Selank's reported tolerability in small trials looks favorable, but long-term human safety data are absent and sourcing quality is the bigger real-world risk. Stacking Selank with Semax: Rationale and Cautions No trials test Selank plus Semax together. Both are unapproved research peptides with limited human data individually; combining them adds untested variables. Selank vs Benzodiazepines: The Comparison People Ask For Selank is not a benzodiazepine and has no FDA approval. Evidence is limited to small Russian trials; dependence data comparable to benzodiazepines does not exist. Selank vs SSRIs and Standard Anxiety Treatment Selank is an unapproved research peptide with small Russian trials; SSRIs and CBT have decades of controlled evidence. Here is how they actually compare. What Is Selank? The Tuftsin-Based Anxiolytic Peptide Selank is a synthetic heptapeptide derived from tuftsin, studied mainly in Russian labs for anxiety and cognition, with no FDA-approved use. KPV Medication Interactions: What We Know and What Is Unstudied No formal KPV drug interaction studies exist. Here is the mechanistic reasoning on immunosuppressants and anti-inflammatories, and when to call your prescriber. How to Get KPV Legitimately: Telehealth, 503A Pharmacies, and Red Flags KPV is not FDA-approved or on the 503A bulks list. Here is why a prescriber and 503A pharmacy still matter, and how to spot gray-market sellers. Showing the first 60 matches. Use search or filters to narrow the library.